Skip Navigation

European Heart Journal 1993 14(3):377-379;
Copyright © 1993 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by MADSEN, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MADSEN, J. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 The European Society of Cardiology

Mortality of patients excluded from the Danish Verapamil Infarction Trial II

J. KOERSTZ MADSEN, J. FISCHER HANSEN and THE DAVIT-II STUDY GROUP

Department of Cardiology, Hvidovre Hospital Copenhagen, DK-2650 Hvidovre, Denmark

Received 23 September 1992; .

Correcpondence: Johnny Koerstz Madsen, Department of Cardiology, Hvidovre Hospital, Kettegåird Alle, DK-2650 Hvidovre, Denmark

Abstract

The 18 month mortality rate in 2180 patients excluded from the Danish Verapamil Infarction Trial II (DAVIT II) was 25.6%. In non-consenters (n = 368) this was 15.0% compared with 13.8% in 897 placebo-treated patients (hazard ratio 1.09 [P = 0.60] when adjusting for sex and age). The increased mortality rate in excluded patients is attributed to heart failure (45.8% and other severe diseases (38.9%).

Key Words: Secondary prevention • acute myocardial infarction • mortality


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.